Abstract:T cells play a critical role in allograft rejection. T-cell activation requires antigen recognition by the T-cell receptor (TCR)/CD3 complex and costimulation of accessory receptors. Non-FcR-binding anti-CD3ε antibodies (Abs) produce immunosuppression without the toxicity associated with Fc-dependent activation (1). Non-FcR-binding anti-CD3ε Abs may induce T-cell anergy, skew the T-cell repertoire toward the Th2 phenotype, modulate the TCR, and block antigen recognition (1). We have found that a critical mechanism of immunosuppression by non-FcR-binding anti-CD3ε Abs is the induction of apoptosis in antigen-activated T cells (2). Among the costimulatory receptors on T cells, CD28 has a pivotal role in the initiation and maintenance of T-cell responses. In various transplant models, inhibition of CD28:B7 interactions by CTLA4-Ig resulted in immunosuppression (3). However, treatment with anti-CD28 Abs was more effective than CTLA4-Ig in the prevention of graft-versus-host disease in mice (4). Therefore, selective targeting of CD28 may be a better approach to achieve transplantation tolerance than blocking B7 molecules, the ligands for both CD28 and CTLA4, as CTLA4 is inhibitory for T-cell activation. Here we tested the hypothesis that combined treatment with non-FcR-binding anti-CD3ε plus anti-CD28 Abs leads to transplantation tolerance by affecting independent and complementary pathways of T cell activation. The experiments were performed in the context of a strong allogeneic MHC stimulation by transplanting skin grafts from BALB/c (H2d) onto C57BL/6 (H2b) mice. Recipients were treated with control Ab, anti-CD28 alone, non-FcR-binding anti-CD3ε alone, or anti-CD3ε plus anti-CD28. As shown in Figure 1A, treatment with anti-CD3 significantly prolonged graft survival compared to control or anti-CD28 treatment (P <0.0001, P <0.0001), whereas anti-CD28 by itself was modestly effective (P =0.002). The combination of anti-CD3ε plus anti-CD28 Abs was significantly more effective than either Ab alone (P =0.002, and P <0.0001), but transplantation tolerance did not develop. We suspected that failure to achieve graft tolerance could result from non-tolerant T cells developing from the thymus after stopping treatment. These T cells could recognize alloantigens and reject the skin graft. To test this hypothesis, we utilized thymectomized C57BL/6 mice as recipients. Treatment with anti-CD3ε plus anti-CD28 Abs significantly prolonged graft survival compared to control Ab (Fig. 1B), but the magnitude of the effect was not significantly different in normal or thymectomized recipients (P =0.5). Figure 1: Prolongation of murine skin allograft survival. Normal (A) or thymectomized (B) C57BL/6 mice were transplanted with full-thickness skin grafts from BALB/c donors. Recipients were intraperitoneally injected with the reagents indicated once every other day for a total of eight doses. The dose of anti-CD3ε and anti-CD28 Abs were 80 and 100 μg/mouse, respectively. The control Ab used was normal hamster IgG.We conclude that anti-CD3 and anti-CD28 Abs have additive immunosuppressive effects, but their combination does not induce tolerance to skin transplants. The failure of inducing transplantation tolerance with this treatment is not caused by the emergence of non-tolerant T cells from the host thymus, but may result from incomplete depletion of alloreactive T cells, lack of inducing T-cell unresponsiveness, and/or lack of generating regulatory T cells. Xue-Zhong Yu1 Yoshio Nitta2,3 Sasha J. Bidwell1 Claudio Anasetti1,4

IL-2 synergy CD45RB mAbs regulate the ratio of Treg/Th17 cells and prolong the survival times of the skin allografts in mice

The roles of IL-2 and IL-10 enhance anti-CD45RBmAb immune inhibition in allograft skin

Tolerance Induced by IL-6 Deficient Donor Heart is Significantly Involved in Myeloid-Derived Suppressor Cells (Mdscs).

Enhanced allogeneic skin-graft survival using sCD95L, sCD152, interleukin-10 and transforming growth factor-β in combination, and comparison with ciclosporin

Cardiac Allograft Tolerance Induced by Isogeneic CD4+CD25+ Regulatory T Cells.

The induction of CD4+CD25+CD127- T cells in an immune tolerance model triggered by engagement of anti-CD45RB mAb

ADDITIVE EFFECTS OF ANTI-CD3 AND ANTI-CD28 ON PROLONGATION OF ALLOGENEIC SKINGRAFT SURVIVAL

An Unexpected Counter‐Regulatory Role of IL‐10 in B‐Lymphocyte‐Mediated Transplantation Tolerance

Dependence relationship between regulatory B cells and regulatory T cells in transplantation immune tolerance

Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation.

Improvement of Transplantation Tolerance of Skin Allograft by Infusion of Donor Bone Marrow Cells and Its Mechanism

A humanized IL-2 mutein expands Tregs and prolongs transplant survival in preclinical models

AdCTLA4-Ig Improves Induction of Transplantation Tolerance to the Allogeneic Skin Allograft in Mice

Regulatory-B Cell and Regulatory-T Cell Collaborate to Promote Transplantation Tolerance (126.2)

Prolonged Survival of Skin Graft by Dendritic Cells Derived Donor-Specific Ilt3 Lentivirus-Transduced Human Cd34(+) Cells in Hu-Nod/Scid Mice

Effects of Combined Immune Therapy on Survival and Th1/Th2 Cytokine Balance in Rat Orthotopic Liver Transplantation

Immunotherapeutic strategy based on anti-OX40L and low dose of IL-2 to prolong graft survival in sensitized mice by inducing the generation of CD4+ and CD8+ Tregs

Anti-ICAM-1 Antibody and CTLA-4Ig Synergistically Enhance Immature Dendritic Cells to Induce Donor-Specific Immune Tolerance in Vivo

4-1BB promotes long-term survival in skin allografts treated with anti-CD45RB and anti-CD40L monoclonal antibodies

Anti-CD45RB and donor-specific spleen cells transfusion inhibit allograft skin rejection mediated by memory T cells.

Inhibition of ICAM-1/LFA-1 interactions prevents B-cell-dependent anti-CD45RB-induced transplantation tolerance.